Contact this trialFirst, we need to learn more about you.
Immunomodulator
Privigen for Systemic Sclerosis
Recruiting1 award3 criteria
Washington, District of Columbia
This trial is researching the effects of Privigen on scleroderma patients' skin, with 24 participants at two hospitals. The goal is to help improve outcomes in this progressive disease.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.